0000000000328816

AUTHOR

Sebastiano Giallongo

showing 6 related works from this author

Additional file of Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin

2021

Additional file of Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin

endocrine systemhemic and lymphatic diseasesheterocyclic compounds3. Good health
researchProduct

Additional file of Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin

2021

Additional file of Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin

endocrine systemhemic and lymphatic diseasesheterocyclic compounds3. Good health
researchProduct

Nociceptin/orphanin FQ opioid receptor (NOP) selective ligand MCOPPB links anxiolytic and senolytic effects

2021

Accumulation of senescent cells may drive age-associated alterations and pathologies. Senolytics are promising therapeutics that can preferentially eliminate senescent cells. Here, we performed a high-throughput automatized screening (HTS) of the commercial LOPAC®Pfizer library on aphidicolin-induced senescent human fibroblasts, to identify novel senolytics. We discovered the nociceptin receptor FQ opioid receptor (NOP) selective ligand 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole (MCOPPB, a compound previously studied as potential anxiolytic) as the best scoring hit. The ability of MCOPPB to eliminate senescent cells in in vitro models was further tested…

Agingmedicine.drug_classNarcotic AntagonistsNOPMCOPPBSenescenceLigandsAnxiolyticMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePiperidinesSenotherapeuticsOpioid receptormedicineAnimalsHumansSenolyticCaenorhabditis elegansReceptorSenolyticCellular Senescence030304 developmental biology0303 health sciencesNOPSenolytic.ChemistryLigand (biochemistry)High-Throughput Screening Assays3. Good healthCell biologyAnalgesics OpioidNociceptin receptorAnti-Anxiety AgentsOpioid PeptidesReceptors OpioidOriginal ArticleGeriatrics and Gerontology030217 neurology & neurosurgeryGeroScience
researchProduct

Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activa…

2020

Rationale: Loss of histone macroH2A1 induces appearance of cancer stem cells (CSCs)-like cells in hepatocellular carcinoma (HCC). How CSCs interact with the tumor microenvironment and the adaptive immune system is unclear. Methods: We screened aggressive human HCC for macroH2A1 and CD44 CSC marker expression. We also knocked down (KD) macroH2A1 in HCC cells, and performed integrated transcriptomic and secretomic analyses. Results: Human HCC showed low macroH2A1 and high CD44 expression compared to control tissues. MacroH2A1 KD CSC-like cells transferred paracrinally their chemoresistant properties to parental HCC cells. MacroH2A1 KD conditioned media transcriptionally reprogrammed parental …

EXPRESSION0301 basic medicineLIVERAdaptive immune systemPOSTTRANSCRIPTIONAL CONTROLHepatocellular carcinomaMedicine (miscellaneous)PROGRESSIONHistone macroH2A1Research & Experimental MedicineCONTRIBUTES03 medical and health sciencesParacrine signalling0302 clinical medicineadaptive immune systemCancer stem cellCANCER STEM-CELLSmedicinechemoresistance.TRANSCRIPTIONIL-2 receptorneoplasmsPharmacology Toxicology and Pharmaceutics (miscellaneous)Tumor microenvironmentScience & Technologybiologyhistone macroH2A1CD44PROLIFERATIONchemoresistanceCancerFOXP3hepatocellular carcinomamedicine.diseaseAcquired immune systemdigestive system diseases3. Good healthCYTOKINE030104 developmental biologyMedicine Research & ExperimentalSENESCENCE030220 oncology & carcinogenesisCancer researchbiology.proteinLife Sciences & BiomedicineChemoresistance
researchProduct

Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin.

2021

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment. A minority of affected patients develops inflammation, subsequently fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCC is a leading cause of cancer-related death. An increased number of senescent cells correlate with age-related tissue degeneration during NAFLD-induced HCC. Senolytics are promising agents that target selectively senescent cells. Previous studies showed that whereas a combination of the senolytic drugs dasatinib and quercetin (D + Q) reduced NAFLD in mice, D + Q lacked efficacy in removing doxorubicin-induced…

0301 basic medicineMaleAgingCirrhosisDasatiniblcsh:MedicineBiochemistrySenolytics.Liver disease0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseSenotherapeuticsNonalcoholic fatty liver diseaseDiethylnitrosamineCancerlcsh:CytologyLiver Diseases3. Good healthDasatinib030220 oncology & carcinogenesisHepatocellular carcinomaDisease ProgressionQuercetinmedicine.symptomLiver diseasemedicine.drugShort ReportInflammationDiet High-Fat03 medical and health sciencesmedicineAnimalsObesitylcsh:QH573-671SenolyticMolecular BiologyInflammationbusiness.industrySenolyticslcsh:RCell Biologymedicine.diseasedigestive system diseasesMice Inbred C57BLDisease Models Animal030104 developmental biologyGene Expression RegulationCancer researchbusinessCell communication and signaling : CCS
researchProduct

Additional file of Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin

2021

Additional file of Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin

Physiology39999 Chemical Sciences not elsewhere classifiedFOS: Chemical sciencesFOS: Biological sciencesFOS: Clinical medicineImmunologyGeneticsBiochemistry69999 Biological Sciences not elsewhere classifiedBiotechnologyCancer
researchProduct